Acredinone C and the Effect of Acredinones on Osteoclastogenic and Osteoblastogenic Activity

J Nat Prod. 2016 Jul 22;79(7):1730-6. doi: 10.1021/acs.jnatprod.6b00004. Epub 2016 Jun 29.

Abstract

A new inhibitor, acredinone C (1), of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation was isolated from the culture broth of the fungus Acremonium sp. (F9A015) along with acredinones A (2) and B (3). The structure of acredinone C (1), which incorporates benzophenone and xanthone moieties, was established by the analyses of combined spectroscopic data including 1D and 2D NMR and MS. All of the acredinones studied efficiently inhibited the RANKL-induced formation of TRAP(+)-MNCs in a dose-dependent manner without any cytotoxicity up to 10 μM. Acredinone A showed dual activity in both osteoclast and osteoblast differentiation in vitro and good efficacy in an animal disease model of bone formation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acremonium / chemistry*
  • Animals
  • Benzophenones / chemistry
  • Benzophenones / pharmacology*
  • Cell Differentiation
  • Disease Models, Animal
  • Mice
  • Molecular Structure
  • Nuclear Magnetic Resonance, Biomolecular
  • Osteoclasts / drug effects
  • Osteogenesis / drug effects
  • RANK Ligand / antagonists & inhibitors

Substances

  • Benzophenones
  • RANK Ligand
  • TNFSF11 protein, human
  • acredinone A
  • acredinone B
  • acredinone C